Comparative Pharmacology
Head-to-head clinical analysis: OXAYDO versus PROPOXYPHENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXAYDO versus PROPOXYPHENE HYDROCHLORIDE.
OXAYDO vs PROPOXYPHENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for mu-opioid receptors, although it can bind to kappa-opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone.
Propoxyphene hydrochloride is a centrally acting opioid analgesic that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of and response to pain.
Oral, 5-10 mg every 4-6 hours as needed for pain; maximum 60 mg per day.
65 mg orally every 4 hours as needed for pain; maximum 390 mg per day.
None Documented
None Documented
Terminal elimination half-life is 3.5-5.5 hours for immediate-release oxycodone; clinically dose every 4-6 hours for sustained analgesia.
6–12 hours (parent drug); norpropoxyphene metabolite half-life 30–36 hours, accumulates with repeated dosing, increasing risk of toxicity, especially in elderly or renal impairment.
Primarily renal as unchanged drug and metabolites; ~90% excreted in urine (approx 10% unchanged oxycodone, rest as noroxycodone and oxymorphone conjugates) and <10% in feces via biliary elimination.
Primarily renal (70-90% as unchanged drug and metabolites, including norpropoxyphene); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic